Ultragenyx Pharmaceutical Inc. (RARE)
Largest Insider Buys in Sector
RARE Stock Price History Chart
RARE Stock Performance
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with …
Insider Activity of Ultragenyx Pharmaceutical Inc.
Over the last 12 months, insiders at Ultragenyx Pharmaceutical Inc. have bought $0 and sold $8.29M worth of Ultragenyx Pharmaceutical Inc. stock.
On average, over the past 5 years, insiders at Ultragenyx Pharmaceutical Inc. have bought $0 and sold $13.23M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $218,150 was made by KAKKIS EMIL D (President & CEO) on 2019‑09‑11.
List of Insider Buy and Sell Transactions, Ultragenyx Pharmaceutical Inc.
| 2024-12-10 | Sale | President & CEO | 8,273 0.0092% | $50.00 | $413,650 | -7.13% | ||
| 2024-10-10 | Sale | Chief Financial Officer | 7,465 0.0077% | $52.76 | $393,853 | -9.30% | ||
| 2024-09-03 | Sale | President & CEO | 20,000 0.0218% | $55.85 | $1.12M | -6.42% | ||
| 2024-09-03 | Sale | SVP, Chief Accounting Officer | 91 <0.0001% | $56.19 | $5,113 | -6.42% | ||
| 2024-08-06 | Sale | President & CEO | 20,000 0.0223% | $50.17 | $1M | +7.09% | ||
| 2024-07-02 | Sale | director | 584 0.0007% | $40.98 | $23,932 | 0.00% | ||
| 2024-06-12 | Sale | EVP and Chief Legal Officer | 9,806 0.0128% | $45.00 | $441,270 | +13.12% | ||
| 2024-06-10 | Sale | director | 1,737 0.002% | $41.10 | $71,391 | +20.20% | ||
| 2024-05-02 | Sale | EVP and Chief Medical Officer | 354 0.0004% | $43.66 | $15,456 | +11.08% | ||
| 2024-04-18 | Sale | EVP and Chief Medical Officer | 142 0.0002% | $44.10 | $6,262 | +9.04% | ||
| 2024-03-11 | Sale | CBO & EVP | 11,509 0.0144% | $49.93 | $574,644 | -3.03% | ||
| 2024-03-07 | Sale | director | 12,195 0.0147% | $50.88 | $620,443 | -7.43% | ||
| 2024-03-01 | Sale | CBO & EVP | 1,011 0.0012% | $53.76 | $54,351 | -12.26% | ||
| 2024-03-01 | Sale | See Remarks | 4,173 0.0051% | $53.76 | $224,340 | -12.26% | ||
| 2024-03-01 | Sale | EVP and Chief Legal Officer | 3,756 0.0046% | $53.76 | $201,923 | -12.26% | ||
| 2024-03-01 | Sale | EVP & Chief Commercial Officer | 4,768 0.0058% | $53.76 | $256,328 | -12.26% | ||
| 2024-03-01 | Sale | EVP and Chief Medical Officer | 1,238 0.0015% | $53.76 | $66,555 | -12.26% | ||
| 2024-03-01 | Sale | SVP, Chief Accounting Officer | 341 0.0004% | $53.76 | $18,332 | -12.26% | ||
| 2024-02-07 | Sale | President & CEO | 30,000 0.0366% | $45.00 | $1.35M | +5.66% | ||
| 2023-12-29 | Sale | President & CEO | 30,000 0.0365% | $47.87 | $1.44M | -1.76% |
Insider Historical Profitability
| KAKKIS EMIL D | President & CEO | 2195712 2.3777% | $44.22 | 2 | 24 | +13.31% |
| Kassberg Thomas Richard | CBO & EVP | 252823 0.2738% | $44.22 | 1 | 25 | |
| Fust Matthew K | director | 14860 0.0161% | $44.22 | 1 | 6 | |
| FMR LLC | 10 percent owner | 3260240 3.5305% | $44.22 | 1 | 0 | +10.41% |
| Sharp Shalini | EVP, Finance | 97812 0.1059% | $44.22 | 1 | 28 |
Institutional Investor Ownership
| The Vanguard Group | $406.2M | 9.3 | 8.7M | +0.31% | +$1.24M | 0.01 | |
| RTW Investments, LP | $330.9M | 7.58 | 7.09M | +2.9% | +$9.34M | 4.96 | |
| BlackRock | $244.46M | 5.6 | 5.24M | -0.05% | -$124,288.78 | 0.01 | |
| Wellington Management Company | $191.33M | 4.38 | 4.1M | -7.18% | -$14.8M | 0.03 | |
| Sands Capital | $180.2M | 4.13 | 3.86M | -6.28% | -$12.07M | 0.5 |